We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
-0.05%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$381M
AUM Growth
-$49.9M
Cap. Flow
-$22.9M
Cap. Flow %
-6%
Top 10 Hldgs %
22.14%
Holding
176
New
41
Increased
28
Reduced
15
Closed
51

Top Buys

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$4.48M
2
FLUX icon
Flux Power
FLUX
+$4.41M
3
XFOR icon
X4 Pharmaceuticals
XFOR
+$4.41M
4
AFMD
Affimed
AFMD
+$4.38M
5
CLDX icon
Celldex Therapeutics
CLDX
+$4.31M

Top Sells

Rank Stock Value
1
PALI icon
Palisade Bio
PALI
+$7.43M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$7.11M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.25M
4
EPIX
ESSA Pharma
EPIX
+$6.1M
5
ECOR icon
electroCore
ECOR
+$5.95M

Sector Composition

Rank Sector Weight
1 Healthcare 81.97%
2 Financials 5.73%
3 Technology 2.04%
4 Industrials 1.47%
5 Communication Services 1.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRCA icon
51
Verrica Pharmaceuticals
VRCA
$81.6M
$3.2M 0.84%
25,624
-26,889
-51% -$3.02M
AUPH icon
52
Aurinia Pharmaceuticals
AUPH
$2.03B
$3.19M 0.84%
144,000
-184,908
-56% -$2.93M
ADMS
53
DELISTED
Adamas Pharmaceuticals
ADMS
$3.07M 0.81%
625,469
+154,520
+33% +$750K
TCON
54
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$3.04M 0.8%
+39,267
New +$3.32M
MREO
55
Mereo BioPharma
MREO
$48.6M
$3.02M 0.79%
1,250,000
– –
GMED icon
56
Globus Medical
GMED
$11.1B
$2.95M 0.77%
38,500
-32,333
-46% -$2.6M
DDI
57
DoubleDown Interactive
DDI
$591M
$2.82M 0.74%
+160,000
New +$2.73M
IGMS
58
DELISTED
IGM Biosciences
IGMS
$2.79M 0.73%
42,473
– –
KRMD icon
59
KORU Medical Systems
KRMD
$166M
$2.72M 0.71%
954,055
+225,568
+31% +$746K
DYN icon
60
Dyne Therapeutics
DYN
$4.83B
$2.71M 0.71%
166,636
– –
FLUX icon
61
Flux Power
FLUX
$11M
$2.65M 0.7%
+521,972
New +$4.41M
CELC icon
62
Celcuity
CELC
$4.56B
$2.61M 0.68%
145,000
– –
MLTX icon
63
MoonLake Immunotherapeutics
MLTX
$1.54B
$2.49M 0.65%
250,000
– –
TMPM
64
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$2.49M 0.65%
254,000
– –
GRTX
65
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$2.44M 0.64%
300,605
+80,705
+37% +$692K
PHAS
66
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$2.41M 0.63%
775,000
– –
CRDF icon
67
Cardiff Oncology
CRDF
$76.7M
$2.32M 0.61%
348,888
-152,990
-30% -$961K
SRSA
68
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$2.22M 0.58%
+225,000
New +$2.21M
VQS
69
DELISTED
VIQ SOLUTIONS INC
VQS
$2.09M 0.55%
+704,687
New +$2.92M
SNDX icon
70
Syndax Pharmaceuticals
SNDX
$1.79B
$2.06M 0.54%
+108,000
New +$1.8M
KA
71
DELISTED
Kineta, Inc. Common Stock
KA
$2.02M 0.53%
28,000
+10,330
+58% +$732K
PRDS
72
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$1.99M 0.52%
200,000
– –
HCAQ
73
DELISTED
HealthCor Catalio Acquisition Corp. Class A Ordinary Shares
HCAQ
$1.98M 0.52%
200,000
– –
GIW
74
DELISTED
GigInternational1, Inc. Common Stock
GIW
$1.97M 0.52%
+200,000
New +$1.97M
MOBX icon
75
Mobix Labs
MOBX
$25.8M
$1.97M 0.52%
+20,000
New +$1.94M
1 2
3
4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Altium Capital Management held 176 positions worth $381M, down 12% from $431M the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Altium Capital Management withdrew a net $22.9M in Q3 2021, closing 51 positions and reducing 15 holdings. Its most notable exit was Palisade Bio, an estimated $7.43M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier, followed by Financials and Technology.

Against the trend, Altium Capital Management opened a new position in Keros Therapeutics worth $4.99M.

  • Altium Capital Management's largest Q3 2021 buy was Keros Therapeutics: 126,000 shares worth $4.99M.
  • Altium Capital Management added most to Celldex Therapeutics in Q3 2021, an estimated $4.31M increase.
  • Altium Capital Management's biggest Q3 2021 reduction was Crinetics Pharmaceuticals, cutting an estimated $7.11M.
  • Altium Capital Management fully exited Palisade Bio in Q3 2021, selling an estimated $7.43M.
  • Altium Capital Management's ten largest holdings make up 22% of its $381M portfolio in Q3 2021.
  • Altium Capital Management opened 41 new positions and closed 51 in Q3 2021.
  • Altium Capital Management's portfolio value fell 12% quarter-over-quarter to $381M.

Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.